JP2016513105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513105A5 JP2016513105A5 JP2015557534A JP2015557534A JP2016513105A5 JP 2016513105 A5 JP2016513105 A5 JP 2016513105A5 JP 2015557534 A JP2015557534 A JP 2015557534A JP 2015557534 A JP2015557534 A JP 2015557534A JP 2016513105 A5 JP2016513105 A5 JP 2016513105A5
- Authority
- JP
- Japan
- Prior art keywords
- galactose
- glycosylated
- population
- seq
- glycosylated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 claims 8
- 210000002919 epithelial cell Anatomy 0.000 claims 7
- 238000004113 cell culture Methods 0.000 claims 6
- 210000000481 breast Anatomy 0.000 claims 5
- 230000009261 transgenic effect Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241000283707 Capra Species 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims 1
- 241000157302 Bison bison athabascae Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764446P | 2013-02-13 | 2013-02-13 | |
| US61/764,446 | 2013-02-13 | ||
| PCT/IB2014/000867 WO2014125382A2 (en) | 2013-02-13 | 2014-02-13 | Cetuximab with modified glycosylation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513105A JP2016513105A (ja) | 2016-05-12 |
| JP2016513105A5 true JP2016513105A5 (enExample) | 2017-03-09 |
Family
ID=50980328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557534A Pending JP2016513105A (ja) | 2013-02-13 | 2014-02-13 | 改変グリコシル化を有するセツキシマブおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160002330A1 (enExample) |
| EP (1) | EP2956484B1 (enExample) |
| JP (1) | JP2016513105A (enExample) |
| KR (1) | KR20150145225A (enExample) |
| CN (1) | CN105358577A (enExample) |
| AR (1) | AR094779A1 (enExample) |
| AU (1) | AU2014217569B2 (enExample) |
| BR (1) | BR112015019339A2 (enExample) |
| CA (1) | CA2900915A1 (enExample) |
| IL (1) | IL240442A0 (enExample) |
| MX (1) | MX2015010429A (enExample) |
| TW (1) | TW201444871A (enExample) |
| WO (1) | WO2014125382A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| AU2014217561B2 (en) | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
| US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| US10344285B2 (en) | 2014-04-09 | 2019-07-09 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| HUE056009T2 (hu) * | 2015-10-08 | 2022-01-28 | Dna Twopointo Inc | DNS vektorok, transzpozonok és transzpozázok eukarióta genom módosítására |
| EP3400248A4 (en) * | 2016-01-10 | 2019-09-04 | Sorrento Therapeutics, Inc. | IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR |
| US11649291B2 (en) * | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| KR102376545B1 (ko) * | 2017-08-01 | 2022-03-21 | 삼성디스플레이 주식회사 | 플렉시블 디스플레이 윈도우 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| WO2022148549A1 (en) | 2020-01-14 | 2022-07-14 | Babylat Gmbh | Apparatus and method for obtaining protein-enriched fractions from breast milk |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| IL165088A0 (en) * | 2002-05-17 | 2005-12-18 | Kirin Brewery | Transgenic ungulates capable of human antibody production |
| AU2003298787A1 (en) * | 2002-11-27 | 2004-06-23 | Gtc Biotherapeutics, Inc. | Modified antibodies stably produced in milk and methods of producing same |
| CA2450289A1 (en) * | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| ES2417147T3 (es) | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| PT2073842E (pt) * | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| NZ593816A (en) * | 2009-01-22 | 2012-11-30 | Momenta Pharmaceuticals Inc | Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells |
| EP2499245B1 (en) * | 2009-11-11 | 2016-09-14 | Momenta Pharmaceuticals, Inc. | Glycosyl transferase from chinese hamster and related methods |
-
2014
- 2014-02-13 MX MX2015010429A patent/MX2015010429A/es unknown
- 2014-02-13 CA CA2900915A patent/CA2900915A1/en not_active Abandoned
- 2014-02-13 TW TW103104778A patent/TW201444871A/zh unknown
- 2014-02-13 JP JP2015557534A patent/JP2016513105A/ja active Pending
- 2014-02-13 KR KR1020157024950A patent/KR20150145225A/ko not_active Withdrawn
- 2014-02-13 WO PCT/IB2014/000867 patent/WO2014125382A2/en not_active Ceased
- 2014-02-13 BR BR112015019339A patent/BR112015019339A2/pt not_active Application Discontinuation
- 2014-02-13 CN CN201480018266.7A patent/CN105358577A/zh active Pending
- 2014-02-13 AR ARP140100458A patent/AR094779A1/es unknown
- 2014-02-13 US US14/767,089 patent/US20160002330A1/en not_active Abandoned
- 2014-02-13 AU AU2014217569A patent/AU2014217569B2/en not_active Ceased
- 2014-02-13 EP EP14732006.3A patent/EP2956484B1/en not_active Not-in-force
-
2015
- 2015-08-09 IL IL240442A patent/IL240442A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508515A5 (enExample) | ||
| JP2016509019A5 (enExample) | ||
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| JP2012116856A5 (enExample) | ||
| MX2020006213A (es) | Anticuerpos anti-trem2 y metodos relacionados. | |
| CN103562403A8 (zh) | 识别肿瘤起始细胞的抗体和抗原及其应用 | |
| JP2012143232A5 (enExample) | ||
| EA201590208A1 (ru) | Усиление активности т-клеток car путем совместного введения биспецифического антитела | |
| UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| PH12019502730A1 (en) | Method of manufacturing bispecific antibodies and therapeutic use of such antibodies | |
| JP2013538057A5 (enExample) | ||
| JP2011182801A5 (enExample) | ||
| JP2020504101A5 (enExample) | ||
| BR112014005644A2 (pt) | anticorpo anti-alfabetatcr | |
| WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
| HRP20241498T1 (hr) | Antitijela usmjerena protiv t-staničnog imunoglobulina i mucin proteina 3 (tim-3) | |
| JP2017052784A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| WO2015049517A3 (en) | Animal models and therapeutic molecules | |
| WO2015127136A3 (en) | Ebola monoclonal antibodies | |
| CL2007003479A1 (es) | Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto. | |
| JP2015028021A5 (enExample) | ||
| BRPI0821682A2 (pt) | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. |